Hirofumi Nakatomi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hirofumi Nakatomi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Inano
Medical Research Center, Fukushima Medical University, Fukushima 960-1247, Japan
1 shared publication - Akio Morita
Department of Neurological Surgery, Nippon Medical School, Tokyo, Japan
1 shared publication - Akitake Mukasa
Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto City, Japan
1 shared publication - Fumiaki Takahashi
Department of Information Science, Iwate Medical University, Morioka, Japan
1 shared publication - Kiyoshi Saito
Fukushima Medical University
1 shared publication - Masao Kobayakawa
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima City, Japan
1 shared publication
Latest Publications
- Open Access
- 31 January 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 726-739
Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.
- 31 January 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 726-739
Open AccessRationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.